Cart empty

Jobelyn Blog

This is some blog description about this site

Nigerian Scientists confirm the power of Jobelyn to cure Rheumatoid Arthritis in Animal Model.

Scientists from Neuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Nigeria led by Solomon Mukoro P hd. in a recent animal model in vivo study postulates that Jobelyn has the potential to treat Rheumatoid Arthritis in human.

In a recent article published in the journal "Biomedicine & Pharmacotherapy"  https://doi.org/10.1016/j.biopha.2017.12.098  it was reported that Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the physical and psychosocial well being of the patients and a major cause of work disability. Current drugs for its treatment only provide palliative effect, as cure for the disease still remains elusive. Jobelyn® (JB), a potent anti-oxidant and anti-inflammatory dietary supplement obtained from Sorghum bicolor, has been claimed to relieve arthritic pain. Thus, this study was designed to evaluate its effect on inflammatory and biochemical changes as well as neurobehavioural deficits associated with complete Freund-adjuvant (CFA)-induced arthritis in mice. The effect of JB (50, 100 and200 mg/kg) on inflammatory oedema, neurobehavioural deficits, levels of biomarkers of oxidative stress and inflammatory cytokines (tumor necrosis factor-alpha and interleukin-6) induced by 0.1 mL of CFA (10 mg/mL)was evaluated in male Swiss mice. Oral administration of JB (100 and 200 mg/kg) reduced inflammatory paw volume and reversed sensori motor deficits induced by CFA. JB also reduced pain episodes, anxiety and depressive-like symptoms in CFA-mice. The increased level of oxidative stress in the joint and brain tissues of CFA mice was reduced by JB. It also decreased tumor necrosis factor-alpha and interleukin-6 levels induced by CFA inthe joint tissue of mice. These findings suggest that Jobelyn® attenuates inflammatory responses induced by CFA in mice via inhibition of oxidative stress and release of inflammatory cytokines. The ability of JB to attenuate CFA-induced nociception, sensori motor deficits and depressive-like symptom suggests it might improve the quality of life of patients with arthritic conditions

The full research paper could be accessed at:


In an earlier study published in https://doi.org/10.1016/j

.biopha.2017.12.098 (De Gruyter), the authors in article titled Jobelyn® exhibited anti-inflammatory, antioxidant, and membrane-stabilizing activities in experimental models, the authors stated that Jobelyn® (JB) is an African sorghum-based food supplement claimed to be efficacious for the treatment of rheumatoid arthritis (RA). Although in vitro studies confirmed its anti-inflammatory property, no study had shown the effect of JB using in vivo animal models of inflammation. Thus, its effects on acute and chronic inflammation in rats were evaluated in this study.Its effect on rat red blood cell (RBC) lysis was also assessed.

Results: JB (50–200 mg/kg) given orally produced a significant inhibition of acute inflammation induced by carrageenan in rats. It reduced the volume and number of leukocytes in inflammatory fluid in the granuloma air pouch model of chronic inflammation. It further decreased the levels of MDA in the fluid suggesting antioxidant property. JB elevated the concentrations of GSH in inflammatory exudates indicating free radical scavenging activity. It also significantly inhibited RBC lysis caused by hypotonic medium, suggesting membrane-stabilizing property.

The authors concluded that JB has in vivo anti-inflammatory activity, which may be related to its antioxidant and membrane stabilizing properties, supporting its use for the treatment of arthritic disorder.

The full length paper could be accessed at:


Jobelyn is manufactured and marketed by:

Health Forever Product Limited.



It is available on line at:







Continue reading
  1061 Hits
1061 Hits